Cargando…

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients. This study was conducted to identify optimal regimens of BLBLIs in these patients. A Monte Carlo simulati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Ruiying, Sun, Dan, Li, Sihan, Chen, Jiaojiao, Teng, Mengmeng, Yang, Bo, Dong, Yalin, Wang, Taotao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389032/ https://www.ncbi.nlm.nih.gov/pubmed/34439043 http://dx.doi.org/10.3390/antibiotics10080993

Ejemplares similares

Clinical Efficacy and Cost-Effectiveness of β-Lactam/β-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection
por: Dong, Yuzhu, et al.
Publicado: (2020)

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
por: Luci, Giacomo, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation
por: Bakdach, Dana, et al.
Publicado: (2022)

Metallo-β-lactamases immobilized by magnetic zeolitic imidazolate frameworks-8 for degradation of β-lactam antibiotics in an aqueous environment
por: Wang, Quanfang, et al.
Publicado: (2023)

Editorial for the Special Issue: “Targeting β-Lactamases to Fight Bacterial Resistance to β-Lactam Antibiotics”
por: Pozzi, Cecilia
Publicado: (2020)

Chemiluminescence Detection of Hydrogen Sulfide Release by β-Lactamase-Catalyzed β-Lactam Biodegradation: Unprecedented Pathway for Monitoring β-Lactam Antibiotic Bacterial Resistance
por: Gholap, Sachin Popat, et al.
Publicado: (2021)

Time Above All Else: Pharmacodynamic Analysis of Β-Lactams in Critically Ill Patients
por: Landmesser, Katherine, et al.
Publicado: (2021)

Induction of β-Lactamase Activity and Decreased β-Lactam Susceptibility by CO(2) in Clinical Bacterial Isolates
por: Mullen, Nathan, et al.
Publicado: (2017)

Pharmacodynamic optimization of β-lactams in the patient care setting
por: Nicolau, David P
Publicado: (2008)

BADAN-conjugated β-lactamases as biosensors for β-lactam antibiotic detection
por: Au, Ho-Wah, et al.
Publicado: (2020)

Cryptic β-Lactamase Evolution Is Driven by Low β-Lactam Concentrations
por: Fröhlich, Christopher, et al.
Publicado: (2021)

Penicillin-Binding Proteins, β-Lactamases, and β-Lactamase Inhibitors in β-Lactam-Producing Actinobacteria: Self-Resistance Mechanisms
por: Martin, Juan F., et al.
Publicado: (2022)

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
por: Aslan, Abdullah Tarık, et al.
Publicado: (2022)

Time-resolved β-lactam cleavage by L1 metallo-β-lactamase
por: Wilamowski, M., et al.
Publicado: (2022)

Synthesis and biological evaluation of novel β-lactam-metallo β-lactamase inhibitors
por: Shungube, Mbongeni, et al.
Publicado: (2023)

Utilization of Colistin Versus β-Lactam and β-Lactamase Inhibitor Agents in Relation to Acute Kidney Injury in Patients with Severe Gram-Negative Infections
por: Doremus, Casey, et al.
Publicado: (2021)

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams
por: Gonçalves-Pereira, Joao, et al.
Publicado: (2011)

Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
por: Veiga, Rui Pedro, et al.
Publicado: (2018)

Clinically Isolated β-Lactam-Resistant Gram-Negative Bacilli in a Philippine Tertiary Care Hospital Harbor Multi-Class β-Lactamase Genes
por: Abordo, Alecks Megxel S., et al.
Publicado: (2023)

The Importance of Porins and β-Lactamase in Outer Membrane Vesicles on the Hydrolysis of β-Lactam Antibiotics
por: Kim, Si Won, et al.
Publicado: (2020)

Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia
por: Lin, Wei-Ting, et al.
Publicado: (2019)

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales
por: Lomovskaya, Olga, et al.
Publicado: (2023)

β-Lactam Pharmacokinetic/Pharmacodynamic Target Attainment in Intensive Care Unit Patients: A Prospective, Observational, Cohort Study
por: Guilhaumou, Romain, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282
por: O’Donnell, John, et al.
Publicado: (2020)

Structural Variabilities in β-Lactamase (blaA) of Different Biovars of Yersinia enterocolitica: Implications for β-Lactam Antibiotic and β-Lactamase Inhibitor Susceptibilities
por: Singhal, Neelja, et al.
Publicado: (2015)

Theaflavin‐3,3´‐digallate increases the antibacterial activity of β‐lactam antibiotics by inhibiting metallo‐β‐lactamase activity
por: Teng, Zihao, et al.
Publicado: (2019)

Quantitative Insights Into β-Lactamase Inhibitor’s Contribution in the Treatment of Carbapenemase-Producing Organisms With β-Lactams
por: Feng, Yanfang, et al.
Publicado: (2021)

β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources
por: Alfei, Silvana, et al.
Publicado: (2022)

Management of clinical infections of Escherichia coli by new β-lactam/β-lactamase inhibitor combinations
por: Kadry, Ashraf Ahmed, et al.
Publicado: (2022)

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
por: Duda-Madej, Anna, et al.
Publicado: (2023)

Extended-spectrum β-lactamases in Gram Negative Bacteria
por: Rawat, Deepti, et al.
Publicado: (2010)

Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination against New Delhi Metallo-β-Lactamase and Serine-β-Lactamase Co-Producing Escherichia coli and Klebsiella pneumoniae
por: Zhang, Jiayuan, et al.
Publicado: (2023)

Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations
por: Katchanov, Juri, et al.
Publicado: (2018)

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians
por: Principe, Luigi, et al.
Publicado: (2022)

Choosing Optimal Antibiotics for the Treatment of Patients Infected With Enterobacteriaceae: A Network Meta-analysis and Cost-Effectiveness Analysis
por: Han, Ruiying, et al.
Publicado: (2021)

In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates
por: Li, Fu, et al.
Publicado: (2018)

Antibiofilm Activity of β-Lactam/β-Lactamase Inhibitor Combination against Multidrug-Resistant Salmonella Typhimurium
por: Laure, Nana Nguefang, et al.
Publicado: (2022)

1230. Evaluation of the Interplay Between β-lactamases and Porin Production on β-Lactam MICs in Klebsiella pneumoniae
por: Whitney, Alyssa K, et al.
Publicado: (2021)

Neutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-β-Lactamase Inhibitors
por: Reddy, Nakita, et al.
Publicado: (2023)

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex
por: Economou Lundeberg, Elin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1fl75dl1o3s477po52smfr2igh